Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
Public ClinicalTrials.gov record NCT05151471. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Multicenter, Randomized, Double-blind Extension Study to Evaluate the Continued Efficacy and Safety of Oral Edaravone Administered for an Additional Period of up to 48 Weeks Following Study MT-1186-A02 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS), based on the time from the randomization date in Study MT-1186-A02 to at least a 12-point decrease in Revised ALS Functional Rating Score (ALSFRS-R) or death, whichever happens first, over the course of the study or until oral edaravone is commercially available in that country
Study identification
- NCT ID
- NCT05151471
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 202 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 10, 2022
- Primary completion
- Sep 28, 2023
- Completion
- Sep 28, 2023
- Last update posted
- Aug 19, 2026
2022 – 2023
United States locations
- U.S. sites
- 10
- U.S. states
- 10
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Woodland Research Northwest, LLC | Rogers | Arkansas | 72758 | — |
| UF Health Cancer Center/Clinical Trials Office | Gainesville | Florida | 32610-3633 | — |
| Emory University - School of Medicine | Atlanta | Georgia | 30317-2819 | — |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611-2605 | — |
| Johns Hopkins University | Baltimore | Maryland | 21205 | — |
| Neurology Associates, P.C - Lincoln | Lincoln | Nebraska | 68506 | — |
| University Of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15213 | — |
| Nerve And Muscle Center Of Texas | Houston | Texas | 77019 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
| West Virginia University School of Medicine (WVUSoM) - Movement Disorder Clinic | Morgantown | West Virginia | 26506-9180 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05151471, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05151471 live on ClinicalTrials.gov.